Home > ASQ Washington, DC &... > Events > Events & Networking > Event Archives > Biomed/Biotech Special...


Biomed/Biotech Special Interest Group
Where
Kelly's Deli Conference Center
Next to the entrance to 7519 Standish Drive
FDA/CVM Center
Rockville, Maryland 20855
When
Aug 28, 2014
6:00 pm - 8:45 pm
(GMT -5:00) EST
“The Impact of Recent
US Health Care Reform
Legislation
on Patient Care &
NIH Research Agenda
for the Substance Use
Disorders”
To be presented
by
Betty Tai,
PhD
Director,
Center for the Clinical Trial Network
(CCTN)
National
Institute on Drug Abuse
(NIDA)
NIH, US
HHS
Thursday, August 28,
2014
6:00 – 6:20 PM –
Networking; Pizza/drink
6:20 –
8:45 PM – Program
8:45 – 9:00
PM – Door-prizes drawing;
Networking
Online Registration site: http://www.asq509.org/ht/d/DoSurvey/i/35817
Open to Public
–
$5: non-ASQ members
to cover pizza/drink
cost;
Free: ASQ members,
veterans, senior citizens, past speakers,
teachers, students, interns, residents,
postdocs, FDA Commissioner’s Fellows, MJ-DC
members, NTUAADC members, CAPA members, CKUADC
members, CCACC volunteers/employees, FAPAC
members, CBA members, AAGEN members,
Commissioned Corp officers, and current
job-seekers.
Location: Kelly’s
Deli Conference Center, 7519 Standish Place,
Rockville (Derwood, for GPS users), MD
20855
Registration Deadline:
Please register by Thursday noon,
August 28, 2014.
Question: Please
contact Dr. C.J. George Chang, Chair of
Biomed/Biotech SIG, ASQ509;
gchang2008@yahoo.com or 240-793-8425
(cell).
Driving directions:
By Cars: From I-270 (N or S bound): Take Exit
9A and exit from the FIRST right exit; turn
left (east) onto Shady Grove Dr.; turn right
(south) onto Rockville Pike (Route 355); turn
left (east) onto East Gude Dr.; turn left
(north) immediately onto Crabb’s Branch Dr.;
turn left (west) immediately onto Standish
Place. The first building on your right side is
7519 Standish Place; open parking). The venue
is on the first floor with its entrance
opposite to the left side of building main
entrance. By Metro trains: Off from Red Line
Shady Grove Station, and take RideOn Route 59
TOWARD ROCKVILLE and get off from “Calhoun
Place” stop. Standish Place is next to the Bus
stop. Our venue is within 2 min of walking
distance from the
stop.
Summary:
The US Health Care
Reform has its huge impact on behavior care
delivery and research agenda. The Patient
Protection and Affordable Care Act (2010) and
the Mental Health Parity and Addiction Equity
Act (2008) expand substance use disorder (SUD)
care services in the US into general medical
settings. Addiction is a chronic brain
disease with consequences that remain
problematic years after discontinuation of use.
The treatment of SUD must adapt to a
chronic care model offered in an integrated
care system that screens for at-risk patients
and includes services needed to prevent
relapses. The partnering of the health
care system with substance abuse treatment
programs could dramatically expand the benefits
of prevention and treatment of SUD.
Expanding roles of health information
technology is essential to the success of a
chronic care
model.
These changes
brought great opportunities and considerable
challenges to the SUD research communities.
NIDA must embrace these opportunities and
address the
challenges.
Presenter’s
Bio:
Dr. Betty Tai
is the Director of Center for the Clinical
Trials Network, NIDA, NIH, US HHS. For
the past 14 years, Dr. Tai has been the
founding leader of NIDA’s first and largest
Clinical Trials Network. Utilizing her
expertise in clinical psychopharmacology, Dr.
Tai leads a network of academic institutions in
partnership with a wide range of drug treatment
providers to bridge the gap between research
and practice by rapidly translating research
into patient care and by elevating the
standards of drug abuse treatment through
practices that are science based. Under
her leadership, the CTN has been recognized,
nationally and internationally, for its
important contributions to the improvement of
drug abuse
treatment.
Dr.
Tai is also leading NIDA’s efforts in its
Electronic Health Records (HER)
Development/Implementation Task Force
representing NIDA throughout government and the
private sector in a National effort to
establish consensus on data elements and
ensuring that balanced policies are in place to
protect patient privacy as drug abuse treatment
is integrated into mainstream medicine.
The gains she has achieved in a short
period of time to ensure that drug abuse is
part of the EHR enterprise have been
impressive. She is now the lead of NIDA’s
taskforce on the development of chronic care
model for drug treatment to bring treatment
into general medical
settings.
Among her
many awards, Dr. Tai, is the recipient of
American Psychological Association’s Research
Service Award and the J. Michael Morrison Award
from the College on Problems of drug Dependence
(CPPD) recognizing her outstanding
contributions in the scientific administration
of drug abuse
treatment.
This Biomed/Biotech SIG event
is cosponsored by the Monte Jade Science and
Technology Association of Greater Washington
(www.MonteJadeDC.org) and NTU Alumni
Association at DC
(www.ntuaadc.org).